Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Pollyea

Showing results (111-120 of 148) with videos related to

Pageof 15
Sort By:
Cell Research|May 9, 2015
Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeuticsGi-Bang Koo, Michael J Morgan, Da-Gyum Lee, et al.
Cancer Discovery|June 26, 2023
A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based TherapyShanshan Pei, Ian T Shelton, Austin E Gillen, et al.
Haematologica|February 26, 2026
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.
Cancer Discovery|May 24, 2024
Targeting Acute Myeloid Leukemia Stem Cells through Perturbation of Mitochondrial CalciumAnagha Inguva Sheth, Mark J Althoff, Hunter Tolison, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRuben Mesa, Catriona Jamieson, Ravi Bhatia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2023
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib StudyDavid A Sallman, Monzr M Al Malki, Adam S Asch, et al.
Ejhaem|July 18, 2022
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect<sup>®</sup> MDS/AML Disease RegistryDaniel A Pollyea, Tracy I George, Mehrdad Abedi, et al.
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
International Journal of Laboratory Hematology|November 21, 2020
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromesJay L Patel, Mehrdad Abedi, Christopher R Cogle, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Pageof 15

Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
Cell Research|May 9, 2015
Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeuticsGi-Bang Koo, Michael J Morgan, Da-Gyum Lee, et al.
Cancer Discovery|June 26, 2023
A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based TherapyShanshan Pei, Ian T Shelton, Austin E Gillen, et al.
Haematologica|February 26, 2026
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.
Cancer Discovery|May 24, 2024
Targeting Acute Myeloid Leukemia Stem Cells through Perturbation of Mitochondrial CalciumAnagha Inguva Sheth, Mark J Althoff, Hunter Tolison, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRuben Mesa, Catriona Jamieson, Ravi Bhatia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2023
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib StudyDavid A Sallman, Monzr M Al Malki, Adam S Asch, et al.
Ejhaem|July 18, 2022
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect<sup>®</sup> MDS/AML Disease RegistryDaniel A Pollyea, Tracy I George, Mehrdad Abedi, et al.
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
International Journal of Laboratory Hematology|November 21, 2020
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromesJay L Patel, Mehrdad Abedi, Christopher R Cogle, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Pageof 15